M30 consortium meeting Rome
On Tuesday-Wednesday 6-7 June 2023, the consortium is gathering in Rome, Italy, for its M30 consortium meeting, where partners will assess the overall status of the project and the progress made in its last 6 months of activity (M25-M30), based on what agreed during the last consortium meeting in Eindhoven, Netherlands, as well as action items and next steps for the last 6 month of the project. The meeting will be hosted at the Hotel Kolbe, a few steps from the Foro Romano and Palatino archeological area.
For Day 1, the meeting agenda foresees activity updates and discussion of open issues for WPs 2 to 6, articulated within the following sessions:
- WP5-6 – Clinical data acquisition and processing: under the lead of UCL and CHA, the session will make a review of the results of acute and chronic animal experiments, the synthetic geometries and boundary condition generation, as well as data processing into the database for anatomy and function included in the SIMCor VRE Drive.
- WP3 – VRE implementation + component integration and interoperability collective session: under the lead of UTBV, ECRIN and TUE, the session will assess the progress on the VRE implementation, now focused on the development of the user interfaces, and the integration and interoperability aspects of its components, i.e., the VRE Drive data archive, the VRE modelling and simulation environment and the R-statistical environment for in-silico trials.
- WP4 – Definition of standard operating procedures (SOPs): under the lead of the VPH Institute, the session will assess the status of the conception of the remaining two SOPs, i.e., (1) the SOPs for virtual cohorts generation and validation and (2) the SOPs for validation of in-silico models, as well as the further refinement of the already published SOPs in view of the II Regulatory Advisory Board and the overall SOP collection publication to be submitted by the end of the project.
- WP2 – Engagement, communication, dissemination + exploitation session: under the lead of LYN, the session will assess the communication and dissemination activities currently in progress, including patient focus groups in UK, Germany and Austria, the Pills of in-silico medicine video series on in-silico medicine, its methodologies and socioeconomic implications and publications in progress, and the planned ones, including a final video summarising project activities and results, as well as planned publications, including a general SIMCor principle paper summarising our approach and results, with the inviìolvement of all consortium partners. Also, an exploitation open session will assess project KERs and envisaged exploitation routes, including sustainability planning for the SIMCor VRE.
On Day 2, the agenda foresees activity updates and collective discussion sessions for WP7-9, as well as update and activity planning for WP10 and WP1, articulated as follows:
- WP7 – Virtual cohort generation and validation: under the lead of TUE, the session will discuss the status of generation of virtual cohorts of aortic valve disease and heart failure patients, as well as a virtual healthy pig population, including the finalisation of the virtual cohort generator pipeline and its multi-level validation, as well as the ongoing work on the strategy for the mapping of engineering metrics and clinical endpoints of interest for the TAVI and PAPS use cases.
- WP8-9 – Virtual device implantation and device modelling and simulation: this session, under the lead of PHI and BIO, will explore the status of the work on virtual device implantation and effect simulation, including vessel models, fast-deployment models, and engineering endpoint assessment for TAVI and PAPS, as well as the definition of a general workflow of SIMCor models and metholodogies.
- WP10 – Quantification of healthcare, industry and socioeconomic effects: under the lead of IHS and ECRIN, the session will explore the status of the work for the assessment of healthcare and socioeconomic impacts of in-silico trial technologies, leveraging medical literature and clinical trial data, economic literature, interviews with field experts from industry and academia, as well as focus groups and surveys with patients.
- WP1 – Coordination and management: under the lead of LYN, the session will report on the planning of the forthcoming Scientific and Regulatory Advisory Boards, discuss the research strategy for the final months of the project, as well as on potential future funding opportunities leveraging SIMCor results, including Horizon Europe and EIT Health funds.